Salmeterol 100 μg: An analysis of its tolerability in single- and chronic-dose studies

Annals of Allergy, Asthma and Immunology

Volumn 87, Issue 6, 2001, Pages 465-473

  Shrewsbury, S ^a   Hallett, C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; SALMETEROL; SALMETEROL XINAFOATE; ADRENERGIC BETA AGONISTS; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; SALBUTAMOL;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; META ANALYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREMOR; ADOLESCENT; ADULT; CHILD; DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMAN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0035542979     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62259-4     Document Type: Article

References (43)

1. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma
2. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial
3. Inhaled salmeterol and fluticasone: A study comparing monotherapy and combination therapy in asthma
4. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma
5. Salmeterol/fluticasone propionate (50/500μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma
6. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
7. Effect of inhaled formoterol and budesonide on exacerbations of asthma
8. The complementary role of glucocorticoids and long-acting β-adrenergic agonists
9. 2-adrenergic receptor transcription in human lung
10. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation
11. 2-adrenergic receptor function in human nasal mucosa
12. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
13. 2-agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth muscle cells
14. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
15. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease - A 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 μg) with salmeterol (50 μg)
16. The bronchoprotective effect of inhaled salmeterol in preschool children: A dose-ranging study
17. Salmeterol in paediatric asthma
18. Chronic dose-ranging studies with salmeterol
19. Salmeterol: A four week study of a long-acting β-adrenoceptor agonist for the treatment of reversible airways disease
20. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
21. 2 agonist
22. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring
23. Comparison of salmeterol with albuterol in the treatment of mild to moderate asthma
24. Salmeterol xinafoate as maintenance therapy with albuterol in patients with asthma
25. A 12-month comparison of salmeterol with salbutamol in asthmatic patients
26. Dose-response study with high-dose inhaled salmeterol in healthy subjects
27. Acute cardiovascular effects of salmeterol in subjects with stable bronchial asthma
28. A 1-week dose-ranging study of inhaled salmeterol in patients with asthma
29. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study
30. Serevent Nationwide Surveillance Study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment
31. Salmeterol: A study by prescription-event monitoring in a UK cohort of 15,407 patients
32. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
33. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis
34. Effect of hydrocortisone on β-adrenergic receptors in lung membranes
35. Safety and appropriate use of salmeterol in the treatment of asthma
36. 2-adrenoceptor agonist: Comparison with salbutamol in adult asthmatic patients
37. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X
38. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma
39. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects
40. Duration and magnitude of action of 50 and 100 μg of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of cold dry air in subjects with asthma
41. Pilgrim's progress: The effect of salmeterol in older children with chronic severe asthma